Subtle Structural Differences Affect the Inhibitory Potency of RGD-Containing Cyclic Peptide Inhibitors Targeting SPSB Proteins
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126764 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kefa Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Peptides, Cyclic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China, Natural Science Foundation of Top Talent of SZTU.
Abstract (Originalsprache)
The SPRY domain-containing SOCS box proteins SPSB1, SPSB2, and SPSB4 utilize their SPRY/B30.2 domain to interact with a short region in the N-terminus of inducible nitric oxide synthase (iNOS), and recruit an E3 ubiquitin ligase complex to polyubiquitinate iNOS, resulting in the proteasomal degradation of iNOS. Inhibitors that can disrupt the endogenous SPSB-iNOS interactions could be used to augment cellular NO production, and may have antimicrobial and anticancer activities. We previously reported the rational design of a cyclic peptide inhibitor, cR8, cyclo(RGDINNNV), which bound to SPSB2 with moderate affinity. We, therefore, sought to develop SPSB inhibitors with higher affinity. Here, we show that cyclic peptides cR7, cyclo(RGDINNN), and cR9, cyclo(RGDINNNVE), have ~6.5-fold and ~2-fold, respectively, higher SPSB2-bindng affinities than cR8. We determined high-resolution crystal structures of the SPSB2-cR7 and SPSB2-cR9 complexes, which enabled a good understanding of the structure–activity relationships for these cyclic peptide inhibitors. Moreover, we show that these cyclic peptides displace full-length iNOS from SPSB2, SPSB1, and SPSB4, and that their inhibitory potencies correlate well with their SPSB2-binding affinities. The strongest inhibition was observed for cR7 against all three iNOS-binding SPSB proteins.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, College of Life Science and Technology, Jinan University, Guangzhou 510632, China.
- Guangdong Provincial Key Laboratory of Bioengineering Medicine, Guangzhou 510632, China.
- Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center, Guangzhou 510632, China.
- National Engineering Research Center of Genetic Medicine, Guangzhou 510632, China.
- College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
ORCID-Profile: Kefa Li, Jinjin Yang, Hai-Shu Lin, Zhihe Kuang
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Top Talent of SZTU
- Featured Innovation Foundation of Ordinary Higher Education Institutions of Guangdong Province
Zitieren
APA
Li, K., Luo, Y., Hu, W., Yang, J., Zhang, D., Wei, H., You, T., Lin, H. S., & Kuang, Z. (2024). Subtle Structural Differences Affect the Inhibitory Potency of RGD-Containing Cyclic Peptide Inhibitors Targeting SPSB Proteins. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126764
Vancouver
Li K, Luo Y, Hu W, Yang J, Zhang D, Wei H, et al. Subtle Structural Differences Affect the Inhibitory Potency of RGD-Containing Cyclic Peptide Inhibitors Targeting SPSB Proteins. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126764
BibTeX
@article{Li2024,
author = {Li, Kefa and Luo, Yanhong and Hu, Weiwei and Yang, Jinjin and Zhang, Danting and Wei, Huan and You, Tingting and Lin, Hai-Shu and Kuang, Zhihe},
title = {Subtle Structural Differences Affect the Inhibitory Potency of RGD-Containing Cyclic Peptide Inhibitors Targeting SPSB Proteins},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126764}
}
EUVIMED